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ABSTRACT Cell cycle arrest at the G1 checkpoint allows
completion of critical macromolecular events prior to S phase.
Regulators of the GI checkpoint include an inhibitor of cyclin-
dependent kinase, p16ONK4; two tumor-suppressor proteins,
p53 and RB (the product of the retinoblastoma-susceptibility
gene); and cyclin D1. Neither pl6NIK4 nor the RB protein was
detected in 28 of 29 tumor cell lines from human lung,
esophagus, liver, colon, and pancreas. The presence of pl6INK4
protein is inversely correlated with detectable RB or cyclin D1
proteins and is not correlated with p53 mutations. Homozygous
deletions of pl6'K4 were detected in several cell lines, but
intragenic mutations of this gene were unusual in either cell
lines or primary tumors. Transfection of the pl6K4 cDNA
expression vector into carcinoma cells inhibits their colony-
forming efficiency and the p16INK4 expressing cells are selected
against with continued passage in vitro. These results are
consistent with the hypothesis that pl6INK4 is a tumor-
suppressor protein and that genetic and epigenetic abnormal-
ities in genes controlling the G1 checkpoint can lead to both
escape from senescence and cancer formation.
The orderly progression of cells through the cell cycle is
governed by genes encoding proteins transmitting positive
[e.g., activated cyclin and cyclin-dependent kinases (Cdks)]
and negative (e.g., inhibitors of Cdk) signals (1-3). Dysreg-
ulation of these genes can lead to premature entry into the
next phase of the cell cycle prior to completion of critical
macromolecular events, including repair of DNA damage,
and generate genomic instability and neoplastic transforma-
tion (4). Negative regulation ofthe cell cycle occurs at G1 and
G2 checkpoints (4, 5). Phosphorylation of the RB protein by
Cdk and the release of RB-associated proteins-e.g., the
transcription factor E2F-is correlated with the transition
across the G, checkpoint (6-10). The free E2F is then
available to transcriptionally activate genes encoding pro-
teins critical for S-phase function, including deoxynucleotide
biosynthesis (11).
Three inhibitors of activated cyclin-Cdk complexes con-
trolling the G, checkpoint of mammalian cells have recently
been identified. A gene encoding a 21-kDa inhibitor (p21,
WAF1, Cipl, Sdil) of multiple cyclin-Cdk complexes is one
of the downstream effectors of p53-mediated G0 arrest and
apoptosis in response to DNA damage (6, 12-15). p27KiP1, an
inhibitor of cyclin D2-Cdk4, has been linked to G0 arrest of
cells either exposed to transforming growth factor P1 or
undergoing contact inhibition in vitro (16). A third inhibitor,
p16INK4, complexes with cyclin D1-Cdk4 or cyclin D2-Cdk4
and may act in a regulatory feedback circuit with Cdk4,
D-type cyclins, and RB and RB-related proteins (17). Since
genes encoding these and other inhibitors ofactivated cyclin-
Cdk complexes are candidate tumor-suppressor genes, our
investigation of this class ofputative tumor-suppressor genes
was initiated by examining the genomic structure and ex-
pression of p16INK4 in human cell lines and primary tumors.
MATERIALS AND METHODS
Cell Lines. WI-38 (human diploid cell line from normal
embryonic lung tissue); A549, A427, A2182, 866MT,
HuT292DM, DM592, SW1271, SK-Lu-i, Calu-1, Calu-6,
NCI-H526, NCI-N417, NCI-H1155, NCI-H358, NCI-H157,
NCI-H322, NCI-H596, and NCI-H446 (lung cancer cell
lines); Hep 3B, Hep G2, SK-Hep-1, HuH-4, HuH-7, Ha22T/
VGH, HB611, and 2.2.15 (liver cancer cell lines); CAPAN-2
and ASPC-1 (pancreatic cancer cell lines); SK-OV-3 (ovarian
cancer cell line); DLD-1, COLO320, SW480, SW620, HT29,
WIDR, LS174T, HCT-116, SK-CO1, SW948, SW48, SW403,
and HCT-15 (colon cancer cell lines); H9, CCL119, and
CCL120 (leukemia cell lines); MCF7, HLB100, HTB126, and
ZRB75 (breast cancer cell lines); and U-118 (glioma cell line)
were obtained from the American Type Culture Collection.
M9K, M24K, M14M, and M19 were provided by K. Lin-
nainmaa (Finnish Institute of Occupational Health, Helsin-
ki). tc4N was provided by M. Noguchi (National Cancer
Center Research Institute, Tokyo). BEAS2B, HET-1A,
HCE-3, HCE4, HCE-7, and THLE5B were established in
our laboratory (National Cancer Institute).
pl6INI4 Genomic Clones and Fluorescence in Situ Hybrid-
ization (FISH). Genomic clones of the p161NK4 gene were
isolated by high-stringency screening of a AFIXII human
genomic library (Stratagene) with cDNA probes. A 13-kb
p16INK4 genomic insert was subcloned into pBluescript
SK(-) (Stratagene) and labeled for FISH analysis. FISH was
performed by established methods. The stained slides were
counterstained with propidium iodide (for an R banding
pattern) or with 4',6-diamidino-2-phenylindole (DAPI) and
actinomycin D (for a DA-DAPI banding pattern). Alignment
of monochrome digital images was made by direct visualiza-
tion through a triple-bandpass (DAPI/fluorescein/Texas
Red) filter. Between 50 and 100 mitoses were examined.
Chromosome localization was confirmed by PCR analysis
from a commercially available somatic cell hybrid panel
(Bios, New Haven, CT) and by dual labeling with a com-
mercially available B-satellite probe for chromosome 9 (On-
cor).
Southern and Nortern Analyss. HindrlI-digested DNAs
were hybridized with human [a-32P]dCTP-labeled p16INI4
cDNA and ERCC3 probes. Northern blot filters were hybrid-
ized with [a-32P]dCTP-labeled human p161NK4 cDNA and glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) probes.
Abbreviations: Cdk, cyclin-dependent kinase; DAPI, 4',6-diamidi-
no-2-phenylindole; FISH, fluorescence in situ hybridization; SSCP,
single-strand conformation polymorphism.
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Immunoprecipitation and Western Blot Analysis. Protein
lysates were prepared as described (17). Three hundred
micrograms of either 35S-labeled or unlabeled protein was
immunoprecipitated with anti-p16INK4 (17), anti-cyclin D1
(Upstate Biotechnology, Lake Placid, NY), or anti-RB (San-
ta Cruz Biotechnology, Santa Cruz, CA) antibodies. For
detection of radiolabeled proteins, gels were fixed and ex-
posed to x-ray film. For Western blot detection, proteins
were electrophorectically transferred to poly(vinylidene di-
fluoride) membranes (Millipore), probed with antibodies, and
detected by chemiluminescence (DuPont).
PCR and Single-Strand Conformation Polymorphism (SSCP)
Analysis. PCR intronic primers were identified from the
p16INK4 genomic sequence. Primers for exon 1 were (5'-3')
1A, CGGAGAGGGGGAGAGCAG (sense), and 1B, TC-
CCCTTTTTCCGGAGAATCG (antisense). PCR conditions
for amplification of exon 1 consisted of a 5-min denaturation
at 940C, followed by 40 cycles of40 sec at 940C, 40 sec at 550C,
and 90 sec at 720C. Primers for exon 2 were (5'-3') 2A,
CTCTACACAAGCTTCCTTTCC (sense), and 2B, GGGCT-
GAACTTTCTGTGCTGG (antisense). PCR conditions con-
sisted of a 5-min denaturation at 95°C, followed by 40 cycles
of 1 min at 95°C, 1 min at 60°C, and 1 min at 72°C. For SSCP
analysis, 32P-labeled PCR products were heat denatured and
applied to a neutral 6% polyacrylamide gel containing 2, 5, or
10%o (vol/vol) glycerol. For exon 2, PCR product was digested
with Sma I before loading.
Nucleotide Sequence Determination. PCR product was pu-
rified and sequenced by the dideoxy chain-termination
method with a Sequenase kit (United States Biochemical).
Transfection. The 960-bp EcoRI fragment of the p16INK4
cDNA (17) was removed from pBluescript vector and ligated
into the Xba I site of the vector pRc/CMV (Invitrogen). Both
orientations were used to create sense and antisense con-
structs. Cells were transfected with 10 ,g of either pCMV-
p16 sense or pCMV-p16 antisense by use of a Lipofectin
reagent (GIBCO/BRL). Forty-eight hours after transfection,
Calu-6 and SK-OV-3 cells were selected with G418 (GIBCO/
BRL) at 225 and 525 jug/ml, respectively.
Colony-Forming Effciency Experiments. Forty-eight hours
after transfection, HCE-4 cells were replated at a density of
3.3 x 105 cells per dish and M9K cells at 1.0 x 105 cells per
dish. Resistant cell populations were then selected with 199
medium (Biofluids, Rockville, MD) supplemented with 10%o
fetal bovine serum (Biofluids) and G418 at 275 ug/ml
(HCE-4) or LHC-MM medium (Biofluids) with G418 at 600
pag/ml (M9K). Colonies were counted by means of an Auto-
count image analyzer (Dynatech).
Immunocytochemistry. Slides were seeded, fixed, and
stained by conventional methods. p16INK4 protein was ex-
amined with a 1:50 dilution of an immunoaffinity-purified
rabbit antiserum raised against glutathione S-transferase
(GST)-p16NK4 fusion protein (17). Residual antibodies to
GST were absorbed by incubating the affinity-purified anti-
serum with a 50-fold molar excess ofGST at 37°C for 1-3 hr.
Specificity of the affinity-purified antiserum was demon-
strated by suppressing all staining by incubation with a
50-fold molar excess of GST-p16INK4.
RESULTS AND DISCUSSION
The p16INK4 gene was localized by FISH to chromosome
9p21-22 (Fig. 1). Previous cytogenetic and allelic deletion
analyses have demonstrated frequent deletions and rear-
rangements of chromosome 9p in carcinoma of the human
bladder, lung, head and neck, and esophagus (18-21), brain
glioma (22, 23), leukemia (24), mesothelioma (25), and mel-
anoma (26). Therefore, we examined the genomic status and
steady-state levels of pl61NK4 mRNA and protein in cell lines
selected from the above and other tumor types (Fig. 2; Table
1). Homozygous deletions of p16NK4 were found in tumor
cell lines by amplifying DNA with the PCR using specific
intronic primers and were confirmed by Southern blot anal-
ysis in 5 of 5 (100%o) pleural mesothelioma, 7 of 18 (39%o) lung
carcinoma, 1 of 3 (33%) esophageal carcinoma, 1 of 8 (13%)
liver carcinoma, 2 of 3 (67%) acute lymphocytic leukemia, 2
of4 (50%) breast carcinoma, 1 of 1 (100%) glioma and 0 of 13
(0%6) colon carcinoma cell lines (Table 1; Fig. 2A). Expres-
sion of the p16INK4 gene was analyzed in 29 of the above
tumor cell lines (Table 1; Fig. 2B). p16INK4 mRNA and
protein were detected in normal WI-38 human fibroblasts and
the nontumorigenic, simian virus 40 T-antigen-immortalized
human cell lines HET-1A, BEAS2B, and THLESB. In con-
trast, p16INK4 mRNA and protein were not detected in 12 of
28 (43%) and 23 of 29 (79o) tumor cell lines, respectively
(Table 1). The tumor cell lines devoid of detectable p16INK4
mRNA and protein often have homozygous deletions of the
gene (Table 1; Fig. 2A). These data are consistent with the
cytogenetic and allelic analyses ofhuman cancers and tumor
cell lines showing homozygous deletions and the recently
described mutations of the p16INK4 gene, which has been
termed the multiple tumor suppressor 1 (MTS1) (28) or Cdk4
inhibitor gene (29) in human cancers.
FIG. 1. Localization of the pl6INK4
gene to chromosome 9p21-22 by FISH.(Left) DA-DAPI banding pattern. Dual
chromatid Cy3 (indocarbocyanine) label-
'I _ing shows the localization of the genomicp16INK4 probe to both copies of chromo-
some 9p. (Right) Higher-magnification
views of propidium iodide-stained chro-I . E mosomes demonstrate localization of the
fluorescein-labeled probe to 9p21-22.
Propidium iodide-stained chromosome
pairs are from the same mitotic spread.
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Table 1. Expression of pl6INK4, cyclin D1, and RB genes and
genomic status of p16INK4 and p53 genes in normal and neoplastic
human cells
Southern
p16INK
ERCC3 eS 40 m MP
.00.
B Meso-
Lung Esophagus Liver theliorna Color
Northern
p16\K*
GAPDH @ *** *
Western
p 16' -" _
_ _
w
Cyclin Di -
RbSiwb
FIG. 2. (A) Homozygous deletions in cancer cell lines (mesothe-
lioma, M24K; esophageal carcinoma, HCE-3; lung carcinoma,
HuT292DM) compared with normal human fibroblasts (WI-38). (B)
Steady-state levels of p16INK4 and glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) mRNAs and p16INK4, RB, and cyclin D1
proteins in representative cell lines.
Since tumor cell lines expressing p16INK4 mRNA, but not
its translated protein, may harbor nonsense and frameshift
mutations in the p16INK4 gene, DNA from such cell lines was
amplified by PCR with specific primers and then analyzed by
SSCP and DNA sequencing. A lung (866MT) and a liver
(Ha22T/VGH) carcinoma cell line had abnormal SSCP pat-
terns, and DNA sequencing revealed deletions in exon 1 of
the p16INK4 gene (Fig. 3; Table 2). When compared with the
predominantly nuclear localization of p16INK4 protein in
normal cells (WI-38 and HET-1A), p16INK4 was not detected
by immunocytochemistry in 866MT cells, which contain a
p16INK4 mutation (Fig. 4). Several other tumor cell lines had
abnormal SSCP patterns in exon 1 (DLD-1, HCT-116, HCT-
15, and CAPAN-2) or exon 2 (NCI-H157), and some of them
were confirmed by DNA sequencing (Table 2). These dele-
tions and insertions are consistent with the DNA polymerase
slippage model ofendogenous mutagenesis (27) and may have
occurred either in vitro or in vivo. The remaining tumor cell
lines have normal SSCP patterns, suggesting either defects of
p16INK4 mRNA at the level of processing and translation or
enhanced degradation of the pl6INK4 protein.
We also initiated a survey of primary tumors analyzed by
SSCP and DNA sequencing. Tumor-specific SSCP patterns
were not observed in 12 esophageal carcinomas, 7 lung
carcinomas, and 6 liver carcinomas. One germline mutation
was found at codon 127, GCA (Ala) to TCA (Ser). Further
studies are needed to determine whether this alteration is
related to cancer-proneness or is a polymorphism unrelated
to cancer risk. These results and others (30, 31) indicate that
the frequency of intragenic p161NK4 gene mutations in some
types ofprimary tumors (i.e., lung, bladder, kidney, head and
neck, brain, colon, and ovary) is quite low. Nevertheless,
Mori et al. (32) recently reported that mutations of the
pl6INK4 gene were detected in 52% of Japanese esophageal
carcinomas. Although we examined microdissected Chinese
Cell type
Fibroblast
WI-38t
Esophagus
HET-1A*
HCE-4
Lung
BEAS2Bt
866MT
Calu-1
Calu-6
NCI-N417
NCI-H1155
NCI-H358
NCI-H157
NCI-H322
NCI-H596
Liver
THLEOBW
Hep 3B
Hep G2
HuH4
Ha22TIVGH
HB611
Pancreas
ASPC-1
Mesothelioma
M9K
M24K
M14M
M19
M33K
Colon
DLD-1
SW620
HT29
LS174T
HCT-116
SW948
SW403
HCT-15
pl6INK4
DNA (SSCP) p53 Cyclin
Exon 1 Exon 2 mRNA Protein gene* RB Dl
P(W) P(W) + + W + +
P(W) P(W) + + W + +
P(W) P(W) + - M + +
P(W)
A(M)
P(W)
P(W)
P(W)
P(W)
P(W)
P(W)
D
P(W)
P(W)
POW)
POW)
P(W)
A(M)
P(W)
P(W)
P(W)
P(W)
P(W)
P(W)
P(W)
P(W)
P(M)
D
P(W)
P(W)
P(W)
P(W)
P(W)
P(W)
P(W)
P(W) ND
D D
D D
D D
D D
D D
P(M)
P(W)
POW)
POW)
P(M)
P(W)
P(W)
P(M)
P(W)
P(W)
P(ND)
P(W)
ND
P(ND)
P(W)
P(W)
+ w + +
- M + +
- M + +
- M + +
+ M - +
+ M - _
- M + +
- M + +
- M + +
+ M - +
+ + w + +
+ + M - +
+ + w + +
+ - M + +
+ - M + +
+ + w + +
+ - M + +
- - w + +
- - w + +
- - w + +
- - w + +
- - w + +
- M + +
- M + +
- M + +
- w + +
- M + +
- ND + -
- ND + -
- ND + +
See Materials and Methods for sources of cell lines. Glyceralde-
hyde-3-phosphate dehydrogenasemRNA was present in all cell lines.
+, Expression; -, not detected; ND, not done; A, abnormal; P,
present; D, deleted; W, wild type; M, mutant.
*Data from ref. 27.
tHuman diploid cell line from normal embryonic lung tissue.
tHuman epithelial cell line immortalized by simian virus 40 T
antigen.
esophageal carcinoma samples, we did not find any mobility
shifts by PCR-SSCP analysis in exons 1 and 2. One possi-
bility is that there are some false negative cases by PCR-
SSCP analysis. However, we used several conditions for
PCR-SSCP analysis and PCR products of <300 bp were
analyzed by SSCP, which generally has a false negative rate
of <10% (33). Another possibility is that there are different
genetic and environmental factors for esophageal carcino-
genesis between the Japanese and the Chinese.
The functional significance of the loss of p16INK4 was
investigated by transfection of a vector containing the
pl6INK4 cDNA driven by a cytomegalovirus promoter into a
human esophageal carcinoma cell line (HCE-4). The colony-
A
It,
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A
Exon I
cagcgggcggogggagcagc ATG GAG CCG GCG GCG GGG AGC AGC ATG GAG CCT TCG GCT GAC TGG CTG
GCC ACG GCC GCG GCC CGG GGT CGG GTA GAG GAG GTG CGG GCG CTG CTG GAG GCG GGG GCG CTG
CCC AAC GCA CCG MT AGT TAC GGT CGG AGG CCG ATC CAGgtgggtagagggtctgcagcgggagcagggg
Exon 2
tctctggcag GTC ATG ATG ATG GGC AGC GCC CGA GTG GCG GAG CTG CTG CTG CTC CAC GGC GCG GAG
CCC MC TGC GCC GAC CCC GCC ACT CTC ACC CGA CCC GTG CAC GAC GCT GCC CGG GAG GGC TTC
CTG GAC ACG CTG GTG GTG CTG CAC CGG GCC GGG GCG CGG CTG GAC GTG CGC GAT GCC TGG GGC
CGT CTG CCC GTG GAC CTG GCT GAG GAG CTG GGC CAT CGC GAT GTC GCA CGG TAC CTG CGC GCG
GCT GCG GGG GGC ACC AGA GGC AGT MC CAT GCC CGC ATA GAT GCC GCG GAA GGT CCC TCA
Ggtgaggactg
B
..,
OC 6Q
;~iL 0r
C
A CG T
FIG. 3. (A) Genomic sequence of p16INK4 exons 1 and 2 including corrections from previously published sequence (17). (B) Examples of
SSCP analysis of cell lines (866MT, Ha22T/VGH, CAPAN-2, DLD-1). Arrows indicate mobilities of DNA fragments amplified from normal
esophageal tissue sample. (C) DNA sequence analysis of 866MT revealing a 33-bp deletion, which is underlined in A.
forming efficiency of the pl6NK4-transfected cells was 112 +
8 (mean ± SD) compared with 192 ± 3 in the cells transfected
with antisense p16INK4 (68%). A similar degree of inhibition
was found using a human mesothelioma cell line (M9K)
which had homozygous deletion of p16INK4 (53%), whereas
the RB-deficient cell line Hep 3B was inhibited to a lesser
extent (83%). We transfected the p16INK4 expression vector
into Calu-6 and SK-OV-3, which lack p16INK4 expression,
and isolated clones were expanded. SK-OV-3 showed rear-
rangement ofthe p16INK4 gene. Although p16INK4 mRNA was
transiently expressed at 48 hr, p16INK4 protein was not
detected by Western analysis in the expanded cell popula-
tions. Expression of transfected wild-type p53 also reduces
colony-forming efficiency of human cancer cells to varying
degrees and the cells expressing wild-type p53 are selected
against during clonal expansion (34, 35). Therefore, expres-
sion of transfected p16INK4 inhibits growth and is selected
against in these cells.
The finding of homozygous deletions and nonsense point
mutations in cancer cell lines and inhibition oftheir growth by
expression of a transfected p16INK4 gene is genetic and
functional evidence consistent with the hypothesis that
p16INK4 is a recessive tumor-suppressor gene (Fig. 2A; Table
1; refs. 2, 27 and 28). However, additional studies are
required to search for germline mutations that segregate with
cancer in families and to determine the frequency of p16INK4
mutations in a wide spectrum of primary tumors. The spec-
trum of somatic p16INK4 mutations differs from that ofthe p53
gene. p53 mutations are primarily missense (reviewed in refs.
36 and 37), whereas p16INK4 mutations are primarily deletion
and nonsense mutations (Table 2; refs. 28 and 29). This
indicates a loss of function of the p16INK4 gene product with
inhibition of activated cyclin D-Cdk4 phosphorylation of cell
cycle-related substrates, including the RB protein, whereas
missense mutations of p53 can produce both loss of suppres-
sor function and gain of oncogenic activity (38).
The G1 checkpoint can be abrogated by genetic and epi-
genetic mechanisms. Mutations in theRB gene can inhibit RB
protein neutralization of the transcriptional activity of E2F
(reviewed in ref. 39). Therefore, we examined the status of
RB protein in the cell lines (Table 1; Fig. 2B), since loss of
RB protein is positively correlated with RB mutations (re-
viewed in ref. 40). The tumor cell lines containing RB protein
rarely expressed pl61NK4 protein, and conversely, p161NK4-
expressing tumor cell lines rarely had detectable RB protein.
This inverse relationship between expression of p16INK4 and
RB protein is statistically significant (P < 0.0006, Fisher
exact test) and indicates that a mutation in either RB or
p16INK4 is sufficient to disrupt the G1 checkpoint pathway.
p53 mutations do not correlate with either p16INK4 or RB
expression in these tumor cell lines (P = 0.38 and 0.13,
respectively), indicating that p53 participates in an indepen-
dent pathway such as regulation of the G1 checkpoint in
response to DNA damage.
Since cyclin D1 overexpression accelerates entry of cells
into S phase (41, 42), negates the G1 arrest induced by RB
introduced into RB-null cell lines (43, 44), and neoplastically
transforms rat embryo fibroblasts alone or in cooperation
with the EMA or Ha-ras oncogene (45-47), the steady-state
levels of cyclin D1 were analyzed (Fig. 2B; Table 1). Al-
though the expression of p161NK4 and cycin D1 is not
correlated, the positive correlation between RB and cyclin
D1 proteins (P = 0.05) is consistent with the recent obser-
vation of RB protein regulating the expression of cyclin D1
(48).
Continuous, long-term culture may select for cells with loss
of senescence genes. p161NK4 is a candidate for the cellular
senescence gene mapped to chromosome 9 by cell-cell
hybrid analysis of immortal cells (49). The Gj-arrest state of
senescent cells is associated with persistent hypophospho-
rylated RB protein and inactive cyclin-Cdk complexes and,
thus, has much in common with quiescent mortal cells (50).
Functional defects of senescence genes, including p21 (15)
and perhaps p16INK4, would allow cells to escape pro-
grammed senescence and enhance the probability of their
neoplastic transformation.
The overexpression and gene amplification of G1 cyclins;
the mutations in the p16INK4, p53, and RB genes; and the
inactivation of the p53 and RB genes by oncoproteins of
certain DNA viruses such as human papillomavirus implicate
dysregulated control of the G1 checkpoint in carcinogenesis
and tumor progression. The low frequency of p161NK4 muta-
Table 2. Mutations of pl6INK4 in cell lines and primary tumors
Sample Mutation Coding effect Location*
866MT (lung) 33-base deletion Splice alteration Codon 44 base 2 to intron 1 base 13
Ha22T/VGH (liver) 23-base deletion Stop codon in exon 1 Codon 21 base 1 to codon 28 base 2
CAPAN-2 (pancreas) 6-base insertion ACG-GCC (Thr-Ala) Between codons 19 and 20
HCT-116 (colon) 1-base insertion Stop codon in exon 1 Codon 23
Lung primaryt GCA -- TCA Ala -. Ser Codon 127
*Codon numbers are based on numbering 1 at the start codon ATG (Fig. 3A).
tThis mutation was detected both in the tumor and in the corresponding normal tissue.
Proc. Natl. Acad Sci. USA 91 (1994)
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FIG. 4. Immunocytochemical staining of p16INK4 protein. (A) Normal human fibroblasts (WI-38, no counterstain) showed cytoplasmic and
nuclear staining which varied among cells. (B) A nontumorigenic, simian virus 40 T-antigen-immortalized human esophageal epithelial cell line
(HET-1A, no counterstain) showed less intense staining. (C) A lung cancer cell line (866MT, eosin counterstain) was negative.
tions in primary tumors when compared with the high fre-
quency in tumor cell lines indicates that one should be
cautious in extrapolating data from cell lines to primary
tumors. Since p16INK4 may be inactivated in the late stages
of tumor progression, a comparison of primary tumors and
their metastases is warranted.
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